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ABSTRACT
Loss of the tumor suppressor gene AT-rich interactive domain-containing 
protein 1A (ARID1A) has been demonstrated in several cancers, but its prognostic 
role is unknown. We aimed to investigate the risk associated with loss of ARID1A 
(ARID1A-) for all-cause mortality, cancer-specific mortality and recurrence of disease 
in subjects with cancer. PubMed and SCOPUS search from database inception until 
01/31/2015 without language restriction was conducted, contacting authors for 
unpublished data. Eligible were prospective studies reporting data on prognostic 
parameters in subjects with cancer, comparing participants with presence of 
ARID1A (ARID1A+) vs. ARID1A-, assessed either via immunohistochemistry (loss of 
expression) or with genetic testing (presence of mutation). Data were summarized 
using risk ratios (RR) for number of deaths/recurrences and hazard ratios (HR) for 
time-dependent risk related to ARID1A- adjusted for potential confounders. Of 136 
hits, 25 studies with 5,651 participants (28 cohorts; ARID1A-: n = 1,701; ARID1A+: 
n = 3,950), with a mean follow-up period of 4.7 ± 1.8 years, were meta-analyzed. 
Compared to ARID1A+, ARID1A- significantly increased cancer-specific mortality 
(studies = 3; RR = 1.55, 95% confidence interval (CI) = 1.19–2.00, I2 = 31%). Using 
HRs adjusted for potential confounders, ARID1A- was associated with a greater risk 
of cancer-specific mortality (studies = 2; HR = 2.55, 95%CI = 1.19–5.45, I2 = 19%) 
and cancer recurrence (studies = 10; HR = 1.93, 95%CI = 1.22–3.05, I2 = 76%). On 
the basis of these results, we have demonstrated that loss of ARID1A shortened time 
to cancer-specific mortality, and to recurrence of cancer when adjusting for potential 
confounders. For its role, this gene should be considered as an important potential 
target for personalized medicine in cancer treatment.
INTRODUCTION
Recent studies established that cancer development 
depends on both epigenetic and genomic alterations [1, 3]. 
Particularly, genes involved in epigenetic mechanisms 
establishing chromatin structure are frequently mutated in 
various types of human cancers [4–6]. Chromatin structure 
is regulated by two general classes of complexes that 
cooperate dynamically: the first class covalently modifies 
histone tails and the second remodels nucleosomes in 
an ATP-dependent manner. Among ATP-dependent 
chromatin remodelers, the so called Switch/Sucrose Non 
Fermentable (SWI/SNF) complexes, consisting of 9–12 
subunits and possessing ATP-dependent nucleosome 
remodeling activity, are most commonly dysregulated in 
cancer [4, 6]. SWI/SNF complexes remodel nucleosome 
structure and can mobilize nucleosomes both by sliding 
and by catalyzing the ejection and insertion of histone 
octamers, using the energy of ATP. These complexes 
have important roles in gene expression regulation, even 
during lineage specification, and in maintaining stem cell 
pluripotency.
Regarding epigenetic tumor suppression function, 
many studies documented that SWI/SNF inactivation leads 
to increased sensitivity to DNA damage and suggested that 
these complexes have roles in the DNA damage response 
[7, 8]. The SWI/SNF complexes can be divided into two 
broad categories based upon the presence of the AT-rich 
interactive domain containing protein 1A-B (ARID1A/B) 
subunits (BAF complex) or ARID2 and Polybromo 1 
(PBMR1) subunits (PBAF complex). ARID1A is an 
important subunit of the mammalian SWI/SNF complex 
(mSWI/SNF or BAF) that is mutually exclusive of the 
ARID1B subunit. Its expression varies during the cell 
cycle, being highest during G0-G1 and lowest in S and 
G2-M phases [9]. As a subunit of SWI/SNF complexes, 
ARID1A is thought to contribute to specific recruitment of 
its chromatin remodeling activity by binding transcription 
factors and transcriptional coactivator/corepressor 
complexes [10].
Several studies have related ARID1A to 
transcriptional regulation, particularly nuclear hormone-
induced transcription and expression of cell-cycle 
regulators; mutations of ARID1A are frequently seen in 
hormone-responsive cancers, like breast and ovary cancers 
[5, 8, 11, 12]. Tumor suppressor genes are defined as 
“caretakers” if they maintain the integrity of the genome, 
and “gatekeepers” if they control cellular proliferation, 
regulating cell-cycle or promoting apoptosis. There is 
evidence that ARID1A has both these functions and that 
inactivating the tumor suppressor gene through somatic 
mutations and other epigenetic mechanism results in 
promoting tumorigenesis [13].
Although ARID1A has been established as a tumor 
suppressor gene through the discovery of recurrent 
inactivating ARID1A mutations in a broad spectrum of 
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cancers, its prognostic role is still debated. Therefore, we 
aimed to investigate the prognostic role of loss of ARID1A 
(ARID1A-) in people with cancer regarding overall 
mortality, cancer-specific mortality, and recurrence of 
disease, hypothesizing that ARID1A- would be associated 
with a poorer prognosis compared to the presence of 
ARID1A (ARID1A+).
RESULTS
Search results
Altogether, the search yielded 125 non-duplicated 
articles. After excluding 94 articles based on title/abstract 
review, 31 articles were retrieved for full text review. 
Finally, 25 studies including 28 cohorts were included in 
this meta-analysis (Supplementary Figure 1).
Study and patient characteristics
The 28 meta-analyzed cohorts followed 5,651 
participants, divided in 1,701 ARID1A- and 3,950 
ARID1A+ patients, for a mean period of 4.7 ± 1.8 years 
(range: 2–6.9 years) (Supplementary Table 1) [14–38]. 
The median NOS score was 7, with only one study at 
possible high risk of bias (Supplementary Table 2) [33].
The studies were conducted mostly in Asia 
(17 studies, 60.7%) [14, 18–21, 24, 26–28, 30, 31, 33, 
35–38] followed by 10 studies (35.7%) [16, 17, 22, 23, 
25, 29, 32, 34] in North America, and 1 study (3.6%) [15] 
in Australia, without any studies conducted in Europe. 
All studies were published after 2010. Thirteen studies 
(46.4%) [14, 16, 18, 19, 23–25, 28, 35–38] were conducted 
about gynecological cancers, 12 studies (42.3%) [15, 
20, 21, 26, 29–34] about gastrointestinal cancers, and 
three (11.3%) [17, 22, 27] about urological cancers. 
Most studies (N = 25, 89.3%) assessed the presence of 
ARID1A with immunohistochemistry (tissue microarray or 
whole-section immunohistochemistry), while 3 (10.7%) 
assessed the genetic status directly (Supplementary Table 1).
Participants with ARID1A- and ARID1A+ averaged 
62.1 ± 12.6 years and 58.8 ± 11.2 years (p = 0.40), and 
54.9% and 52.7% were females (p = 0.41) (Supplementary 
Table 1). Participants with ARID1A- and ARID1A+, had 
a low stage of cancer according to FIGO (International 
Federation of Gynecology and Obstetrics) in 66.1% and 
87.0% of cases (p = 0.26), with the corresponding figures 
being 53.1% and 63.6% (p = 0.002) using the TNM 
classification. Finally, 47.0% and 51.3% of participants 
with ARID1A- and ARID1A+ had a low grade cancer 
(p = 0.14) (Supplementary Table 1).
Risk ratios of all-cause mortality, cancer 
mortality and recurrence
Pooling data from 26 studies [14–25, 27, 28, 
30–38], 577 (35.3%) of 1,633 participants with ARID1A- 
died vs. 1,204 (32.2%) of 3,735 with ARID1A+, resulting 
in a non-significant group difference (RR = 1.03, 95%CI: 
0.90–1.17, p = 0.69, I2 = 87%) (Table 1; Supplementary 
Figure 2). Similarly, across 7 studies [14, 18, 19, 22, 
27, 28, 35], recurrence of cancer did not differ between 
the two groups, with 98/454 (21.6%) recurrences in 
those with ARID1A- vs. 76/373 (20.4%) in those with 
ARID1A+ (RR = 1.11, 95%CI: 0.98–1.25, p = 0.10, 
I2 = 51%) (Table 1; Supplementary Figure 3). Conversely, 
loss of ARID1A was associated with an increased risk of 
death due to cancer in three studies [16, 17, 27] compared 
to presence of ARID1A (138/303 = 45.5% vs. 25/130 = 
19.2%; RR = 1.55, 95%CI: 1.19–2.00, p = 0.001, 
I2 = 31%) as shown in Table 1 and in Supplementary 
Figure 4.
Table 1: Pooled Risk Ratio Estimates For Overall Survival, Death Due To Cancer And Recurrence 
According To ARID1A Status
Parameter N 
Studies
N of 
Events 
in loss of 
ARID1A 
group
N loss of 
ARID1A 
group
N of 
Events in 
presence 
of 
ARID1A 
group
N 
presence 
of 
ARID1A 
group
Risk 
Ratio(95% 
CI)
P-
Value
Heterogeneity
All-cause 
mortality 26 577 1,633 1,204 3,735
1.03[0.90, 
1.17] 0.69
Tau2 = 0.08; Chi2 = 191.72, 
df = 25 (P < 0.0001); I2 = 87%
Death due 
to cancer 3 138 303 25 130
1.55[1.19, 
2.00] 0.001
Tau2 = 0.02; Chi2 = 2.92, df = 2 
(P = 0.23); I2 = 31%
Recurrence 7 98 454 76 373 1.11[0.98, 1.25] 0.10
Tau2 = 0.01; Chi2 = 12.49, 
df = 6 (P = 0.05); I2 = 51%
Bolded RR values: p < 0.05
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Adjusted hazard ratios for all-cause mortality, 
cancer mortality and recurrence of disease
In secondary analyses, we investigated whether 
using hazard ratios (adjusted for the maximum number 
of the covariates available in each study) instead of risk 
ratios influenced the results. Altogether, the number of 
adjustments ranged from 0 to 10, with a mean of 3 ± 3 
covariates used in the survival analyses (Supplementary 
Table 1).
Pooling data from 19 studies [14, 15, 17, 19, 21, 
22, 25, 27, 28, 30, 33, 35, 37, 38], ARID1A- was still 
not associated with a greater risk of all-cause mortality 
(HR = 1.17, 95%CI: 0.84–1.63, p = 0.36, I2 = 67%). 
Conversely, in adjusted survival analyses, compared to 
ARID1A+, ARID1A- was associated with a significantly 
greater risk of dying from cancer (2 studies) [17, 27]; 
HR = 2.55, 95%CI: 1.19–2.41, p = 0.02, I2 = 19%) and 
of experiencing a recurrence of cancer (10 studies) [14, 
18, 19, 22, 27–29, 32, 35]; HR = 1.93, 95%CI: 1.22–3.05, 
p = 0.005, I2 = 76%) (Table 2; Figures 1, 2; Supplementary 
Figure 5).
Meta-regression and sensitivity analyses
Univariable meta-regression analyses yielded 
only very few significant moderators for outcomes 
with high heterogeneity and sufficient number of 
studies (i.e., all-cause mortality and recurrence of 
cancer and corresponding analyses with adjusted HRs) 
(Supplementary Table 3). For all-cause mortality and 
cancer recurrence, only differences in percentage of low-
grade cancers between ARID1A- vs. ARID1A+, country, 
and number of adjustments were significant moderators, 
while for adjusted hazard ratios no significant moderators 
were evident (Supplementary Table 3).
In multivariable meta-regression analyses, 
significant moderators emerged only for all-cause 
mortality, including differences in percentage of low-grade 
cancers between ARID1A- vs. ARID1A+ and studies 
about gastrointestinal and gynecological cancers compared 
to urological cancers (Supplementary Table 4).
Among the moderators considered for stratification 
(i.e., body system, country, and study quality), no 
significant moderators emerged explaining the absence of 
an association between ARID1A- and all-cause mortality 
(even when considering adjusted HRs), while loss of 
ARID1A was significantly associated with the number 
of recurrences of urological cancers (RR = 1.15, 95%CI: 
1.07–1.23, p < 0.0001, I2 = 0%) and studies conducted 
in non-Asian countries (RR = 1.16, 95%CI: 1.04–1.28, 
p = 0.005) (Supplementary Table 5). Considering adjusted 
HRs instead of number of cancer recurrences, studies 
of urological cancers (HR = 2.25, 95%CI: 1.60–3.15, 
p < 0.0001, I2 = 78%) and those conducted in Asia 
(HR = 2.37, 95%CI: 1.54–3.66, p < 0.0001, I2 = 88%) 
significantly moderated the association between loss of 
ARID1A and risk of cancer recurrence adjusting survival 
analyses for potential confounders (Supplementary 
Table 5). Quality of studies was not significantly related 
to any of the analyzed outcomes.
Publication bias
Funnel plots inspection indicated that publication 
bias was unlikely.
DISCUSSION
To our knowledge, this is the first meta-analysis 
investigating the relationship between loss of ARID1A 
and prognosis or outcome in patients with cancer. We 
examined 25 prospective, observational studies involving 
28 cohorts with 5,651 participants (ARID1A-: n = 1,701; 
ARID1A+: n = 3,950) during a mean period of 4.7 ± 
1.8 years. As hypothesized, since ARID1A has been 
described as a potential tumor suppressor gene, loss of 
ARID1A was associated with increased cancer-specific 
mortality as well as recurrence of cancer when adjusting 
for potential confounders in survival analyses, while no 
effect was evident for all-cause mortality. Due to the high 
heterogeneity in four of the six meta-analyzed outcomes, 
a series of meta-regression and sensitivity analyses was 
Table 2: Pooled Risk Ratio Estimates For Adjusted Hazard Ratios For Overall Survival, Death 
Due To Cancer And Recurrence According To ARID1A Status
Parameter N Studies Hazard Ratios(95% CI) P-Value Heterogeneity
All-cause mortality 19 1.17[0.84, 1.63] 0.36 Tau
2 = 0.32; Chi2 = 54.31, df = 18 
(P < 0.0001); I2 = 67%
Death due to cancer 2 2.55 [1.19-5.45] 0.02 Tau
2 = 0.06; Chi2 = 1.25, df = 1 (P = 0.26); 
I2 = 19%
Recurrence 10 1.93 [1.22-3.05] 0.005 Tau
2 = 0.38; Chi2 = 37.55, df = 9 
(P < 0.0001); I2 = 76%
Bolded RR values: p < 0.05
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Figure 2: Pooled Hazard Ratio (Adjusted For Potential Confounders) For Recurrence According To ARID1A Status. 
Figure 1: Pooled Hazard Ratio (Adjusted For Potential Confounders) For All-Cause Mortality According To ARID1A 
Status. 
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conducted. Only all-cause mortality seemed to be partially 
affected by differences in low-grade tumors between 
ARID1A+ and ARID1A- as well as by different cancer 
types, i.e., gastrointestinal/gynecological vs. urological 
cancers. When stratifying for some potential moderators, 
loss of ARID1A increased the risk of cancer recurrence 
for urological cancers, while study origin in Asia yielded 
conflicting results. Notably, however, the pre-analytic 
and analytic variability of immunohistochemical analysis 
techniques is well-known, which could explain the 
conflicting results of some studies and the heterogeneity of 
the results. Thus, further studies are needed to address this 
point also for IHC, ideally developing a well-standardized 
analytic system.
Assessing the ARID1A mutational status in different 
types of cancers allows for a more differentiated risk 
evaluating. The discordance between cancer-specific 
mortality and time to recurrence on the one hand and all-
cause mortality on the other may potentially be due to 
the fact that people with cancer often have many other 
co-morbidities and die of causes that are not directly 
linked to the ARID1A expression status. Furthermore, 
we speculate that loss of ARID1A could be involved in 
the progression of cancer or be correlated with locally 
invasive growth, mechanisms that could have less 
importance when a cancer is in a late stage. The expression 
of ARID1A may also be associated with different cancer 
stages [17–22]. For example, Wei et al. reported that 
ARID1A- was significantly associated with all-cause 
mortality only in stage IV patients [31]. Furthermore, 
Yokoyama et al. reported no differences regarding overall 
mortality between ARID1A+ and ARID1A- patients; 
yet, they described a significant association between 
disease free survival and ARID1A status, but only in 
TNM stage III-IV cancer patients [35]. Notably, these 
authors described a significant association between loss of 
ARID1A and chemoresistance suggesting that ARID1A- 
may be a factor more important for predicting the risk of 
recurrence, affecting more the disease free survival than 
overall survival [35]. In order to determine whether the 
expression level of ARID1A has any effect on overall 
survival, further prospective studies are needed, ideally 
differentiated by stage.
Loss of ARID1A function is associated with 
dysregulation of the PI3K/Akt signaling pathway, which 
may have a synergistic effect on tumor development 
[39, 40]. Moreover, an inverse relationship has been 
documented between ARID1A and TP53 in uterine 
endometrioid [40, 41], gastric [29] and esophageal 
carcinomas [42], and between ARID1A and Phosphatase 
and TENsin homologue (PTEN) in colorectal and 
serous ovarian carcinomas [7]. Furthermore, a very 
important issue in the prognostic analysis associated 
with ARID1A mutational status can be related to defects 
in mismatch repair, of which microsatellite instability 
(MSI) is the phenotype. MSI involves short repeats of 
mono- or oligonucleotides that are typically also present 
in ARID1A, and MSI is associated with a remarkably high 
rate of sequence mutation in cancer cells [13]. ARID1A 
mutation has been associated with MSI in gastrointestinal 
cancers [15, 29]. Lastly, ARID1A- has been reported to 
be correlated with Epstein-Barr virus (EBV)-associated 
gastric cancers [43]. Wang et al. found ARID1A mutations 
in 47% of EBV-infected, microsatellite stable gastric 
tumor samples, which was significantly higher than in 
microsatellite stable gastric tumors without EBV-infection 
(percentage not indicated in the paper) [29]. MSI and 
EBV-infection are associated with better prognosis and 
are also associated with ARID1A loss. Considering both 
MSI and EBV infection, ARID1A loss was correlated 
with poor prognosis only in gastric cancers without 
MSI and EBV infection [43]. Thus, due to this complex 
interplay between partially offsetting interactions, it will 
be important for better understanding the prognostic 
role of ARID1A to identify the stages and subgroups in 
different types of cancers that can be affected by ARID1A 
mutational status.
From the targeted therapy’s point of view, 
interestingly, a recent systematic review of genetic 
vulnerability across cancer cell lines identified ARID1B, 
the ARID1A mutually exclusive subunit in mSWI/SNF 
(BAF) complex, as the top gene required for cancer 
cell survival with inactivating ARID1A mutations [44]. 
ARID1B was required for the stable assembly of BAF 
complex in ARID1A- cells. Silencing ARID1B impaired 
cellular proliferation in cancer cells with ARID1A 
mutations, but not in cells with wild-type ARID1A, 
suggesting that ARID1B is a potential therapeutic target 
for cancers with ARID1A mutation. The involvement 
of ARID1A in maintaining genomic stability makes 
cancers with ARID1A mutations potential candidates 
for therapeutic approaches based on synthetic lethality: 
an ARID1A-deficient tumor, with its intrinsic genomic 
instability, may be vulnerable to therapies targeting 
molecular pathways involving genome maintenance. Due 
to the possible correlations between ARID1A mutations 
and other pathways (e.g. PI3K pathway), it will be 
interesting to investigate the effect of inhibitors of other 
pathways on tumors with different ARID1A mutational 
status. With more emerging epigenetic cancer therapies, 
it will be important to better understand the landscape of 
ARID1A-containing mSWI/SNF targets and the epigenetic 
alterations that follow ARID1A mutations. The goal is 
the application of personalized medicine to ARID1A 
deficient tumors and perhaps even to precancerous lesions, 
generating a next-generation histopathologic diagnosis 
[45, 46]. Despite these very heterogeneous genetic and 
epigenetic interactions of ARID1A with other important 
molecular mechanisms, our statistically significant results 
of the prognostic value of ARID1A mutation on cancer 
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recurrence and death due to cancer have relevant research 
implications.
The findings of our meta-analysis, however, should 
be interpreted within its limitations, the most important of 
which is represented by the heterogeneity of the results. 
It is likely due to the fact that the included studies had 
different baseline characteristics (in particular regarding 
tumor grading and stage) that could affect the results. 
Taking as example all-cause mortality, differences in low-
grade cancers partly explained the heterogeneity of our 
findings. Therefore, future studies with more homogeneity 
of tumor grading and stage are needed, at least in subgroup 
analyses. Furthermore, we were not able to control our 
analyses for some factors that are independently associated 
with overall or cancer-specific mortality or with cancer 
recurrence, including smoking, number/type of medical 
morbidities and medications, and obesity, because they 
are not analysed in the selected papers. Lastly, about one 
half of the included studies did not consider other genes, 
although these are likely important too since ARID1A is 
involved in several pathways. Therefore, in the future the 
ability to adjust for the mutations of other genes could 
be fundamental for a better interpretation of the role of 
ARID1A and cancer outcomes.
In conclusion, loss of ARID1A shortened time 
to cancer-specific mortality as well as to recurrence of 
disease when adjusting for potential confounders. Since 
many types of neoplasms are characterized by loss of 
ARID1A, further studies are needed to find ways to 
leverage ARID1A findings for developing targeted 
therapeutic interventions and understand more in depth 
the heterogeneity of the results.
MATERIALS AND METHODS
Data sources and literature search strategy
Two investigators (C.L., N.V.) independently 
conducted a literature search using PubMed and SCOPUS 
without language restriction, from database inception until 
01/31/2015, for prospective studies comparing all-cause 
mortality, cancer mortality and recurrence of cancer in 
patients with a diagnosis of cancer with loss vs. presence 
of expression of ARID1A. In PubMed and SCOPUS, 
controlled vocabulary terms and the following keywords 
were used: (“ARID1A” OR “AT-rich interactive domain-
containing protein 1A” OR “BAF250a”) AND (“cancer” 
OR “neoplasm” OR “carcinoma”) AND (“Mortality” OR 
“Mortalities” OR “Case Fatality Rate” OR “Case Fatality 
Rates” OR “Death Rate” OR “Death Rates” OR “survival” 
OR “prognosis” OR “hazard ratio” OR HR OR “relative 
risk” OR RR). Conference abstracts and reference lists 
of included articles and those relevant to the topic were 
hand-searched for identification of additional, potentially 
relevant articles. Any inconsistencies were resolved by 
consensus.
Study selection
Inclusion criteria for this meta-analysis 
were: 1) prospective, observational cohort study, 
2) immunohistochemical or genetic investigation of 
ARID1A, 3) diagnosis of cancer, 4) data about mortality 
or cancer recurrence. Since most mutations in ARID1A are 
insertions or deletions, resulting in a truncated protein that 
is prone to rapid degradation, ARID1A gene mutations 
are highly associated with loss of protein expression. 
For this reason, we included also the studies based on 
immunohistochemical analysis, which can be used as a 
surrogate marker for the underlying gene mutation.
Exclusion criteria were: 1) no presence of cancer, 
2) no data about relevant outcomes in the title/abstract, 
3) did not compare patients with ARID1A- vs ARID1A+, 
and 4) in vitro or animal studies.
Data extraction
Two investigators (N.V. and M.S.) extracted key 
data from the included articles and a third independent 
investigator (C.C.) checked these data. For each article, 
we extracted data about authors, year of publication, 
country, type of cancer, exclusion criteria, other genes or 
proteins analyzed, participant characteristics according to 
ARID1A status (e.g., age, percentage of females, tumor 
stage and grading), methods of ARID1A assessment, 
number of adjustments in survival analysis, and duration 
of follow-up (Supplementary Table 1). When some 
information about ARID1A or outcomes was missing, first 
and/or corresponding authors of the original article were 
contacted at least four times to obtain unpublished data.
Outcomes
The primary outcomes were number of deaths 
independent of the cause (all-cause mortality), number of 
deaths due to cancer, and number of cancer recurrences 
after treatment (e.g., chemotherapy, surgery, radiotherapy) 
during follow-up period depending on the loss or the 
presence of ARID1A.
Assessment of study quality
We used the Newcastle-Ottawa Scale (NOS) (http://
www.ohri.ca/programs/clinical_epidemiology/oxford.htm) 
to evaluate study quality, with a score of ≤ 5 (out of 9) 
indicating high risk of bias (Supplementary Table 2) [47]. 
This systematic review was conducted following the 
Meta-Analysis Of Observational Studies in Epidemiology 
(MOOSE) guidelines and Preferred Reporting Items 
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for Systematic reviews and Meta-Analyses (PRISMA) 
statement [48, 49].
Data synthesis and statistical analysis
Analyses were performed using Comprehensive 
Meta-Analysis (CMA) 3 (http://www.meta-analysis.com).
 In primary analyses, pooled risk ratios (RRs) and 
95% CIs of all-cause mortality, cancer mortality and 
recurrences in patients with ARID1A+ and ARID1A- 
tumors were calculated using DerSimonian-Laird random-
effects models [50]. In secondary analyses, pooled, hazard 
ratios (HRs) with 95%CIs adjusted for the maximum 
number of covariates available, were also calculated 
for providing additional information if the relationship 
between ARID1A status and outcomes was influenced 
by potential confounders. Heterogeneity across studies 
was assessed by the Cochrane I2 metric and chi square 
statistics. Given significant heterogeneity (p < 0.05), 
we conducted a series of univariable and multivariable 
meta-regression analyses according to ARID1A status 
considering each of the outcomes [51].
The following moderators were tested: country 
(Asia vs. other continents), body system (urological, 
gastrointestinal, or gynecological), sample size, study 
quality (NOS score), number of adjustments, methods of 
the assessment of ARID1A, duration of follow-up, and 
differences between ARID1A+ and ARID1A- in age, 
percentage of females, tumor stage (divided in Tumor, 
Nodes, Metastasis (TNM) stage 1–2, indicating low 
stage, and TNM 3–4, indicating higher stage), tumor 
grading (divided in G1–2, indicating low grade, and 
G3–4, indicating higher grade). Any moderators with a 
p-value ≤ 0.10 in univariable meta-regression analyses 
for a specific ARID1A contrast group were entered into 
a backward elimination multivariable meta-regression 
analysis for that ARID1A contrast group.
We also conducted stratified analyses exploring 
effects of the following pre-specified moderators: body 
system (gastrointestinal, gynecological or urological), 
study origin (Asia vs. other continents), and study quality 
(median split of the NOS score [NOS = 7]). All final 
inferential statistics used alpha = 0.05.
Lastly, we assessed the presence of publication bias 
by visual inspection of Funnel plots.
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